Correction to: Clinical and Experimental Medicine (2024) 25:10
https://doi.org/10.1007/s10238-024–01524-8.
In the original version of the article, the entries in Table 1 was misaligned.
Table 1 which previously appeared as
Table 1. Baseline characteristics of Hodgkin lymphoma patients
| Total cohort n = 68 |
HIV+ ve n=21 (31%) |
HIV- ve n=47 (69%) |
P-value | |
|---|---|---|---|---|
| Female | 34 (51%) | 10 (48%) | 24 (51%) | 0.793 |
| Median age (years) |
36 (IQR 26 – 52) |
39 (IQR 28–46) |
33 (IQR 25–57) |
0.841 |
| PLWH receiving ART | 18 (86%) | |||
|
CD4 count median (cells/ul) * <100 100–200 >200 |
152 (IQR 105–286) 5 (25%) 6 (30%) 9 (45%) |
|||
| EBV tumour positive** | 33 (49%) | 20 (95%) | 13 (28%) | <0.001 |
|
Stage at diagnosis I II III IV |
1 (2%) 13 (19%) 9 (13%) 45 (66%) |
0 4 (19%) 1 (5%) 16 (76%) |
1 (2%) 9 (19%) 8 (17%) 29 (62%) |
0.552 |
|
Histological subtype Nodular sclerosing Lymphocyte rich Mixed cellularity Lymphocyte depleted CHL unclassified*** |
37 (54%) 12 (18%) 10 (15%) 1 (1%) 8 (12%) |
6 (29%) 2 (10%) 5 (24%) 1 (5%) 7 (33%) |
31 (66%) 10 (21%) 5 (11%) 0 1 (2%) |
<0.001 |
|
Chemotherapy treatment Died before treatment/no treatment First line only First & second line |
1 (1%) 52 (76%) 15 (22%) |
1 (5%) 17 (81%) 3 (14%) |
0 35 (74%) 12 (26%) |
0.244 |
|
Survival at last follow up Alive Deceased |
56 (82%) 12 (18%) |
14 (67%) 7 (33%) |
42 (89%) 5 (11%) |
0.037 |
ART antiretroviral therapy; CHL classical Hodgkin lymphoma; PLWH people living with HIV; IQR interquartile range*1 patient did not have a CD4 count available**Detected by EBERish (for lymph node and tissue) and LMP-1 staining (for bone marrow biopsies)***All CHL unclassified cases were diagnosed on bone marrow biopsy
But should have been
Table 1. Baseline characteristics of Hodgkin lymphoma patients
| Total cohort n = 68 |
HIV+ ve n=21 (31%) |
HIV- ve n=47 (69%) |
P-value | |
|---|---|---|---|---|
| Female | 34 (51%) | 10 (48%) | 24 (51%) | 0.793 |
| Median age (years) |
36 (IQR 26 – 52) |
39 (IQR 28–46) |
33 (IQR 25–57) |
0.841 |
| PLWH receiving ART | 18 (86%) | |||
|
CD4 count median (cells/ul) * <100 100–200 >200 |
152 (IQR 105–286) 5 (25%) 6 (30%) 9 (45%) |
|||
| EBV tumour positive** | 33 (49%) | 20 (95%) | 13 (28%) | <0.001 |
|
Stage at diagnosis I II III IV |
1 (2%) 13 (19%) 9 (13%) 45 (66%) |
0 4 (19%) 1 (5%) 16 (76%) |
1 (2%) 9 (19%) 8 (17%) 29 (62%) |
0.552 |
|
Histological subtype Nodular sclerosing Lymphocyte rich Mixed cellularity Lymphocyte depleted CHL unclassified*** |
37 (54%) 12 (18%) 10 (15%) 1 (1%) 8 (12%) |
6 (29%) 2 (10%) 5 (24%) 1 (5%) 7 (33%) |
31 (66%) 10 (21%) 5 (11%) 0 1 (2%) |
<0.001 |
|
Chemotherapy treatment Died before treatment/no treatment First line only First & second line |
1 (1%) 52 (76%) 15 (22%) |
1 (5%) 17 (81%) 3 (14%) |
0 35 (74%) 12 (26%) |
0.244 |
|
Survival at last follow up Alive Deceased |
56 (82%) 12 (18%) |
14 (67%) 7 (33%) |
42 (89%) 5 (11%) |
0.037 |
The original version of this article has been corrected.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.